Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 27 of 97, showing 5 Applications out of 482 total, starting on record 131, ending on 135

# Protocol No Study Title Investigator(s) & Site(s)

131.

ECCT/22/06/01   The INSIGHT cohort
      A cohort for evaluation of open-label PrEP delivery and PrEP preferences among African women        
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI RCTP, LUMUMBA SUBCOUNTY HOSPITAL
 
View

132.

ECCT/22/05/03   Anti-malaria MAb in Kenyan chi
    Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium falciparum, in an Age De-Escalation, Dose-Escalation Trial and a Randomized, Placebo-Controlled, Double-Blind Trial of Children in Western Kenya   
Principal Investigator(s)
1. Titus Kwambai
2. Laura Steinhardt
3. Robert A Seder
Site(s) in Kenya
1. Siaya County Referral Hospital (Siaya county)
2. Kogelo Health Center (Siaya county)
 
View

133.

ECCT/22/05/02   BREATHER Plus
        A randomised open-label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-Saharan Africa   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
Moi University Clinical Research Centre
 
View

134.

ECCT/22/05/01   VICTORION-2 PREVENT
    A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with   established cardiovascular disease   
Principal Investigator(s)
1. Anthony Gikonyo
2. ELIJAH SAMMY NYAINDA OGOLA
Site(s) in Kenya
1. The Karen Hospital (Nairobi City county)
2. Centre for research in Therapeutic Sciences (CREATES (Nairobi City county)
 
View

135.

ECCT/22/04/02   GO42144
    A PHASE Ia/Ib DOSE-ESCALATION AND DOSE- EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITYOF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS        
Principal Investigator(s)
1. Mansoor Noorali Saleh
Site(s) in Kenya
Aga Khan University, Nairobi
 
View